| Ytd | -60.89% | |
| 1y | -31.60% |
| Open | 2.02 | Prev Close | 2.02 | Low | 2.01 | High | 2.10 | Mkt Cap | 290.40M |
| Vol | 1.62M | Avg Vol | 7.86M | EPS | -0.41 | P/E | -5.12 | Forward P/E | -10.86 |
| Beta | 0.90 | Short Ratio | 12.39 | Inst. Own | 88.00% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-05 | 50-d Avg | 2.09 | 200-d Avg | 4.29 | 1yr Est | 13.64 |
Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical compa
BOSTON, July 17, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stag
Compass Therapeutics is rated Buy, with risk/reward favoring upside after a sharp post-data selloff.
U.S. stock futures mixed with Dow futures down 0.1%. Domino's Pizza misses earnings expectations
Organon & Co (OGN) jumped 14.8% in pre-market trading as Sun Pharma agreed to acquire the compan
U.S. stocks traded lower this morning, with the Dow Jones dropping more than 100 points on Tuesday.
Tuesday's session saw 729 companies set new 52-week lows.